|
EVERYTHING
Shutdown Fight Centers on Obamacare Subsidies That Could Vanish
What: Democrats say they won’t vote to reopen the government unless Obamacare subsidies, set to expire next year, are extended. Without the subsidies, premiums will rise for more than *20 million people* and about two million are expected to lose coverage, with increases as high as over $1,000 for older people in expensive markets.
Key Line: “The subsidies, first passed in 2021 and extended in 2022, make health insurance less expensive for nearly all those who buy their own coverage. Since the subsidies’ creation, enrollment in Obamacare markets has more than doubled.”
My Take: This matters for women’s health, especially pregnant women who make too much money to qualify for Medicaid but don’t get insurance through an employer, and women who are retired but not yet on Medcare. Women make up 52% of people enrolled in Obamacare plans nationwide, but in states like Kentucky, it’s as high as nearly 60%.
Source: New York Times
Why Women’s Health Tech Stalls Despite Big Investments
What: Veronica Adamson of Harvard’s public health school argues that low hospital reimbursements, heavy regulatory burdens, costly infrastructure, and cultural stigma keep Femtech discoveries from reaching patients, even when the science is promising and investors are interested. Adams highlights the example of fetal monitors that haven’t been improved in decades — and even when a big company tried to improve them, they failed.
Key Line: “These monitors are inefficient, overwhelmingly prone to false positives, and clinically unreliable. Ninety-nine percent of the time, when the fetal monitor alarms to signal that the baby may be in danger, it’s wrong. Interpreting fetal monitoring strips, it turns out, is similar to asking doctors to read tea leaves during one of the most important moments in a family’s life. …At first, I thought it would be just like scaling any other new product. We launched first-of-their-kind innovation partnerships and pursued upgrades to fetal monitoring systems. …But then reality set in. Despite strong internal commitment and promising data, it was clear that widespread adoption would take long-term persistence against regulatory friction, reimbursement shortfalls, and structural barriers. It wasn’t a question of will, patients’ need for the product, or technical capability — it was a system calibrated to sustain the status quo.”
My Take: A key challenge Adamson highlights is how much OBGYNs actually get paid for labor and delivery. That rate is largely set by a very arcane system relying on a committee of doctors called “Medpac.” And the problem is that all their changes have to be “budget neutral”…so if OBGYNs get a pay raise, another specialty gets a pay cut.
Source: StatNews
Government Shutdown Freezes Women’s Health Research
What: You may not yet feel it in your daily life, but we are officially in a government shutdown. The Society for Women’s Health Research points out that has halted most federally-funded work, including health research. NIH is freezing grant awards, delaying new clinical trials, and furloughing staff, putting women’s health research—already chronically underfunded—at even greater risk.
Key Line: “Shutdowns don’t just pause progress – they destabilize the scientific enterprise. …The ripple effects will be felt not only in research labs, hospitals, and universities, but also in the lives of women waiting for better treatments and answers to urgent health issues.”
My Take: I don’t think this shutdown will last as long as it did in 2018 (over a month), but SWHR makes a great point that it only takes a few days to start throwing carefully planned scientific research off track.
Source: Society for Women’s Health Research
ABORTION ACCESS
FDA Approves Second Generic Abortion Pill
What: Just before the government shutdown, the FDA quietly approved a second generic version of mifepristone, the pill used alongside misoprostol in most U.S. abortions. The new product comes from Evita Solutions, joining GenBioPro’s version approved in 2019, and was deemed therapeutically equivalent to the brand-name Mifeprex. The move drew praise from abortion rights advocates who called medication abortion safe and essential healthcare, and sharp criticism from anti-abortion groups pressing for tighter restrictions.
Key Line: “Andrew Nixon, a spokesperson for the Health and Human Services Department, said the FDA does not endorse drug products and directs prescribers to follow all labeling. ‘The FDA has very limited discretion in deciding whether to approve a generic drug. By law, the Secretary of Health and Human Services must approve an application if it demonstrates that the generic drug is identical to the brand-name drug,’ Nixon said in a statement.”
My Take: The statement above is just another example of the needle the Trump administration is trying to thread. Last week the FDA commission says they must look at safety based on a religious organization’s white paper, this week they say they had to approve the new generic version of the drug. It’s impossible to tell what they really believe.
Source: NBC News
MENOPAUSE
FDA Weighs Softening Black Box Warning on Menopause Hormone Therapy
What: FDA commissioner Martin Makary told CNN that the agency may soon change the strongest warning on hormone replacement therapy (HRT) products for menopause symptoms, which for two decades has highlighted risks like breast and uterine cancer, stroke, blood clots, and dementia. Critics argue the broad warning has scared off patients and doctors, even for lower-risk treatments like vaginal creams or skin patches, and has left millions of women undertreated for severe hot flashes, sleep problems, and vaginal dryness. A review of evidence suggests risks differ by age, timing, and delivery method, and experts are divided on whether the warning is still justified in its sweeping form.
Key Line: “‘It’s really a tragedy. It’s maybe one of the greatest screw-ups of modern medicine,’ Makary said. ‘It’s resulted in 50 million women being denied this incredible therapy.’”
My Take: It’s hard enough to find information on menopause recommendations, much less parse the back and forth on a study over 20 years ago that overhyped risks. I suspect changing the label will be most meaningful to doctors who get alerted to these changes — but if you polled Americans on what “black box” warnings were, I’d guess maybe 5-10% would know.
Source: CNN
|